Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.

Viking Therapeutics’ lead obesity candidate VK2735 (dual GLP-1/GIP agonist) is expected to face a long wait for Phase 3 readouts—78-week subcutaneous results likely not until Q3 2027 and oral results not until 2028–2029—keeping the stock volatile. Near-term catalysts include Phase 3 oral program initiation in Q4 2026 and results from a 19-week Phase 1 maintenance dosing trial on tolerability during subcutaneous-to-oral transition, following prior safety/tolerability concerns that drove a summer 2025 selloff. With the stock down ~66% from its early-2024 peak and ~8.4% YTD in 2026, upcoming trial data could shift sentiment, but the lack of definitive Phase 3 efficacy keeps expectations cautious.

Analysis

VKTX is trading more like an event-driven option than a fundamentals story: the market is being asked to discount a multi-year commercial outcome while the only verifiable catalysts are near-term tolerability readouts and trial-start execution. That usually keeps a single-asset biotech in a high beta/low conviction regime, where small data deltas can re-rate the stock 20-40% in either direction without changing the end-state probability much. The key second-order issue is financing: every quarter of delay pushes out de-risking while burn continues, so even good science can be diluted by capital raises before phase 3 data arrives.

For incumbents, LLY and NVO are not direct stock price victims from one maintenance study, but a credible oral-maintenance pathway is strategically relevant because persistence is the real economic moat in obesity, not just headline weight loss. If VKTX can show that patients can bridge from injection to oral with tolerability intact, it pressures the idea that the class must remain anchored to chronic injectables and could increase churn risk at the margin in the 2027-2029 launch window. Conversely, if the maintenance data reinforces the prior oral tolerability concerns, the market will likely re-flag VKTX as a pre-commercial dilution story rather than a platform winner.

The contrarian point is that the stock may be more sensitive to safety/tolerability than efficacy at this stage, because efficacy is already broadly assumed to be competitive. The consensus is probably underweighting how much the oral transition matters operationally: if patients do not persist through the switch, the dual-formulation thesis loses most of its strategic value. Falsifier for a bullish view is any readout that leaves open a meaningful GI discontinuation problem or forces trial-design changes; that would likely cap the multiple for months even if the program survives.

Key Decisions for Investors

• Do not chase the equity ahead of the maintenance readout; treat VKTX as a binary catalyst name with dilution risk over the next 6-12 months.
• If implied volatility is modest relative to the event, express upside via a limited-risk VKTX call spread into the maintenance data rather than stock; target a 2-3x premium payoff if the oral bridge looks clean.
• Use any post-data selloff of >15-20% on non-fatal tolerability noise to initiate a starter long only if the readout preserves the dual-formulation thesis; exit if the market starts pricing in trial redesign or slower oral initiation.
• Avoid shorting LLY/NVO as a hedge; the read-through is too remote for the mega-caps. If hedging biotech beta is needed, pair any VKTX long with a small XBI short to isolate idiosyncratic catalyst risk.
• Watch for phase 3 program timing and any financing language in the next 1-2 quarters; a delayed start or capital raise would be the clearest sign that the current valuation is still too optimistic.